Picard Medical Securities Class Action Notice

Written by Emily J. Thompson, Senior Investment Analyst

Source: Globenewswire

Updated: Feb 25 2026

0mins

PMI+18.75%

Should l Buy PMI?

Source: Globenewswire

Class Action Deadline: Purchasers of Picard Medical securities are reminded that April 13, 2026, is the deadline to apply as lead plaintiff, and those who bought shares between September 2 and October 31, 2025, may be entitled to compensation without any out-of-pocket costs.
Lawsuit Background: The lawsuit alleges that Picard Medical's management failed to disclose significant adverse facts regarding the company's business and securities trading during the class period, misleading investors and impacting their decision-making.
Law Firm Credentials: Rosen Law Firm specializes in securities class actions, having recovered over $438 million for investors in 2019 alone, highlighting its successful track record, which investors should consider when selecting legal counsel.
Investor Action Steps: Investors can visit the Rosen Law Firm's website or call the toll-free number for more information on joining the class action, ensuring they receive appropriate legal representation throughout the litigation process.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy PMI?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on PMI

About PMI

Picard Medical, Inc. is a holding company that owns a 100% interest in SynCardia Systems, LLC (SynCardia). SynCardia is a medical technology company that manufactures and sells the only United States Food and Drug Administration (FDA) and Health Canada-approved implantable total artificial heart (SynCardia TAH). The SynCardia TAH is a biventricular replacement device that consists of the SynCardia TAH implant, an external pneumatic driver that delivers precisely calibrated pulses of air to drive the implant, and drivelines that connect the driver to the implant. The SynCardia TAH implant is a system that consists of two independent artificial ventricles which are powered by an external pneumatic driver. Each artificial ventricle is made of a semi-rigid polyurethane housing and a rigid polyurethane base, with a four-layer flexible polyurethane diaphragm separating the blood chamber from the air chamber.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Picard Medical Faces Class Action Lawsuit

15 hours agoGlobenewswire

Fraud Allegations Unveiled: Robbins LLP has alerted investors that Picard Medical (PMI) is facing a class action lawsuit for allegedly engaging in a fraudulent stock promotion scheme related to securities transactions between September 2 and October 31, 2025, which could severely impact the company's reputation and stock price if proven true.
Stock Price Crash: On October 24, 2025, Picard Medical's stock price plummeted by 70%, dropping from approximately $13.30 to $3.99 per share, and has since continued to decline to around $2.00, indicating extreme market concern regarding the company's financial health.
Insider Trading Investigation: The lawsuit alleges that company executives and affiliates used offshore or nominee accounts for coordinated share dumping, failing to disclose false information and artificial trading activities to investors, which could lead to legal repercussions and further loss of investor trust.
Shareholder Action Guidance: Affected shareholders can file to become lead plaintiffs in the class action by April 3, 2026, and even those who choose not to participate can still be eligible for recovery, highlighting potential flaws in corporate governance and the impact on shareholder rights.

Multiple Companies Face Class Action Lawsuits

17 hours agoGlobenewswire

Richtech Robotics Class Action: Richtech Robotics Inc. is facing allegations for failing to disclose its claimed relationship with Microsoft during the class period from January 27 to January 29, 2026, misleading investors about the company's prospects, with a lead plaintiff deadline of April 3, 2026.
Picard Medical Fraud Allegations: Picard Medical, Inc. is accused of being involved in a fraudulent stock promotion scheme from September 2 to October 31, 2025, which included misinformation on social media and insider trading, with investors needing to file a lead plaintiff motion by April 3, 2026, to address potential losses.
Plug Power Misrepresentation: Plug Power, Inc. is alleged to have overstated the availability of funds related to a DOE loan during the class period from January 17 to November 13, 2025, leading to investor misconceptions about future projects, with a lead plaintiff deadline of April 3, 2026.
Legal Consultation Advisory: Affected investors are encouraged to contact The Law Offices of Frank R. Cruz to understand their legal rights and potential losses related to these class actions, ensuring they are informed about their options for participation.

Picard Medical Investors Warned of Significant Losses

19 hours agoGlobenewswire

Legal Investigation: Faruqi & Faruqi, LLP is investigating potential claims against Picard Medical (NYSE: PMI) and reminds investors to apply by April 13, 2026, to seek the role of lead plaintiff in a federal securities class action to protect their legal rights.
Stock Price Plunge: On October 24, 2025, Picard Medical's shares plummeted from $13.20 to $5.31, a staggering drop of $7.89 or approximately 59.8%, marking one of the most significant single-day declines since the company's IPO.
False Promotion Allegations: The lawsuit alleges that Picard Medical and its executives violated federal securities laws by engaging in fraudulent stock promotion schemes involving misinformation on social media and insider trading, severely undermining investor confidence and the company's reputation.
Investor Rights Protection: Faruqi & Faruqi is seeking information from anyone aware of Picard Medical's conduct, including whistleblowers and former employees, to support affected investors and ensure their rights are protected in the legal proceedings.